Differentiation of schizophrenia using structural MRI with consideration of scanner differences: A real-world multisite study.


Journal

Psychiatry and clinical neurosciences
ISSN: 1440-1819
Titre abrégé: Psychiatry Clin Neurosci
Pays: Australia
ID NLM: 9513551

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 02 04 2019
revised: 07 09 2019
accepted: 13 09 2019
pubmed: 7 10 2019
medline: 24 11 2020
entrez: 7 10 2019
Statut: ppublish

Résumé

Neuroimaging studies have revealed that patients with schizophrenia exhibit reduced gray matter volume in various regions. With these findings, various studies have indicated that structural MRI can be useful for the diagnosis of schizophrenia. However, multisite studies are limited. Here, we evaluated a simple model that could be used to differentiate schizophrenia from control subjects considering MRI scanner differences employing voxel-based morphometry. Subjects were 541 patients with schizophrenia and 1252 healthy volunteers. Among them, 95 patients and 95 controls (Dataset A) were used for the generation of regions of interest (ROI), and the rest (Dataset B) were used to evaluate our method. The two datasets were comprised of different subjects. Three-dimensional T1-weighted MRI scans were taken for all subjects and gray-matter images were extracted. To differentiate schizophrenia, we generated ROI for schizophrenia from Dataset A. Then, we determined volume within the ROI for each subject from Dataset B. Using the extracted volume data, we calculated a differentiation feature considering age, sex, and intracranial volume for each MRI scanner. Receiver-operator curve analyses were performed to evaluate the differentiation feature. The area under the curve ranged from 0.74 to 0.84, with accuracy from 69% to 76%. Receiver-operator curve analysis with all samples revealed an area under the curve of 0.76 and an accuracy of 73%. We moderately successfully differentiated schizophrenia from control using structural MRI from differing scanners from multiple sites. This could be useful for applying neuroimaging techniques to clinical settings for the accurate diagnosis of schizophrenia.

Identifiants

pubmed: 31587444
doi: 10.1111/pcn.12934
pmc: PMC6972978
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-63

Subventions

Organisme : Brain/MINDS
ID : JP18dm0207006
Organisme : Brain/MINDS beyond
ID : JP18dm0307002
Organisme : Grants-in-Aid for Scientific Research
ID : JP16H05375
Organisme : Grants-in-Aid for Scientific Research
ID : JP18K18164
Organisme : Grants-in-Aid for Scientific Research
ID : JP25293250
Organisme : Japan Agency for Medical Research and Development
ID : 16dk0307031h0003

Informations de copyright

© 2019 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.

Références

Neuroimage Clin. 2017 Nov 08;17:563-569
pubmed: 29201642
Neuroimage. 2010 Feb 1;49(3):2123-33
pubmed: 19913626
Schizophr Bull. 2004;30(2):393-404
pubmed: 15279055
Biol Psychiatry. 1999 Aug 1;46(3):374-82
pubmed: 10435203
Mol Psychiatry. 2016 Apr;21(4):547-53
pubmed: 26033243
Schizophr Bull. 2013 Sep;39(5):1129-38
pubmed: 23042112
Neuroimage. 2011 Apr 1;55(3):856-67
pubmed: 21236349
Am J Psychiatry. 2000 Apr;157(4):581-7
pubmed: 10739417
Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409
pubmed: 15925493
Bioinformatics. 2005 Oct 15;21(20):3940-1
pubmed: 16096348
Arch Gen Psychiatry. 2005 Nov;62(11):1218-27
pubmed: 16275809
Am J Psychiatry. 2004 May;161(5):896-902
pubmed: 15121656
Neuroimage. 2007 Jan 1;34(1):235-42
pubmed: 17045492
Neuroimage. 2013 Jan 15;65:167-75
pubmed: 23041336
Schizophr Bull. 2018 Aug 20;44(5):1035-1044
pubmed: 29186619
Neuropsychopharmacology. 2015 Jun;40(7):1742-51
pubmed: 25601228
BMC Med Imaging. 2011 Jan 25;11:3
pubmed: 21266047
Schizophr Res. 2009 Mar;108(1-3):104-13
pubmed: 19157788
Biol Psychiatry. 2008 Nov 1;64(9):774-81
pubmed: 18486104
Inf Process Med Imaging. 2009;21:300-13
pubmed: 19694272
Front Aging Neurosci. 2014 Oct 17;6:260
pubmed: 25368574
Psychiatry Clin Neurosci. 2018 Aug;72(8):556-571
pubmed: 29717522
Schizophr Res. 2001 Apr 15;49(1-2):1-52
pubmed: 11343862
Psychiatry Clin Neurosci. 2012 Dec;66(7):611-7
pubmed: 23252928
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Clin Biochem Rev. 2008 Aug;29 Suppl 1:S83-7
pubmed: 18852864
Am J Psychiatry. 2005 Dec;162(12):2233-45
pubmed: 16330585
Mol Psychiatry. 2016 Oct;21(10):1460-6
pubmed: 26782053
Schizophr Res. 2011 Apr;127(1-3):46-57
pubmed: 21300524
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:116-25
pubmed: 23261522
Neuroimage. 2007 Feb 15;34(4):1405-15
pubmed: 17188902
Arch Gen Psychiatry. 2011 May;68(5):489-95
pubmed: 21536978
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7
pubmed: 25601291

Auteurs

Kiyotaka Nemoto (K)

Department of Psychiatry, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Tetsuya Shimokawa (T)

Center for Information and Neural Networks, National Institute of Information and Communications Technology, Osaka, Japan.

Masaki Fukunaga (M)

Division of Cerebral Integration, National Institute for Physiological Sciences, Aichi, Japan.

Fumio Yamashita (F)

Division of Ultrahigh Field MRI, Institute for Biomedical Sciences, Iwate Medical University, Iwate, Japan.

Masashi Tamura (M)

Department of Psychiatry, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Hidenaga Yamamori (H)

Department of Pathology of Mental Diseases, National Center of Neurology and Psychiatry, National Institute of Mental Health, Tokyo, Japan.
Japan Community Health Care Organization, Osaka Hospital, Osaka, Japan.
Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.

Yuka Yasuda (Y)

Department of Pathology of Mental Diseases, National Center of Neurology and Psychiatry, National Institute of Mental Health, Tokyo, Japan.
Life Grow Brilliant Mental Clinic, Osaka, Japan.

Hirotsugu Azechi (H)

Department of Pathology of Mental Diseases, National Center of Neurology and Psychiatry, National Institute of Mental Health, Tokyo, Japan.

Noriko Kudo (N)

Department of Pathology of Mental Diseases, National Center of Neurology and Psychiatry, National Institute of Mental Health, Tokyo, Japan.

Yoshiyuki Watanabe (Y)

Department of Future Diagnostic Radiology, Osaka University Graduate School of Medicine, Osaka, Japan.

Mikio Kido (M)

Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.

Tsutomu Takahashi (T)

Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.

Shinsuke Koike (S)

University of Tokyo Institute for Diversity & Adaptation of Human Mind (UTIDAHM), Tokyo, Japan.
Center for Evolutionary Cognitive Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.
The International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced Study (UTIAS), Tokyo, Japan.
UTokyo Center for Integrative Science of Human Behavior (CiSHuB), The University of Tokyo, Tokyo, Japan.

Naohiro Okada (N)

The International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced Study (UTIAS), Tokyo, Japan.
Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Yoji Hirano (Y)

Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Toshiaki Onitsuka (T)

Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Hidenori Yamasue (H)

Department of Psychiatry, Hamamatsu University School of Medicine, Shizuoka, Japan.

Michio Suzuki (M)

Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.

Kiyoto Kasai (K)

University of Tokyo Institute for Diversity & Adaptation of Human Mind (UTIDAHM), Tokyo, Japan.
The International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced Study (UTIAS), Tokyo, Japan.
UTokyo Center for Integrative Science of Human Behavior (CiSHuB), The University of Tokyo, Tokyo, Japan.
Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Ryota Hashimoto (R)

Department of Pathology of Mental Diseases, National Center of Neurology and Psychiatry, National Institute of Mental Health, Tokyo, Japan.
Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.

Tetsuaki Arai (T)

Department of Psychiatry, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH